Metamark Genetics, J&J deal

Johnson & Johnson's Janssen Biotech Inc. unit partnered with Metamark to identify cancer targets using Metamark's Prognosis Determinant discovery technology. Janssen can select targets for exclusive licensing and would be responsible for discovery, development and commercialization of therapies against the targets. ...